The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 31, 2020

Filed:

Jan. 20, 2015
Applicant:

Boehringer Ingelheim Vetmedica Gmbh, Ingelheim am Rhein, DE;

Inventors:

Saskia Kley, Appenheim, DE;

Dania Birte Reiche, Bingen am Rhein, DE;

Assignee:

Other;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/351 (2006.01); C07D 309/10 (2006.01); A61K 38/28 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 9/02 (2006.01); A61K 31/7034 (2006.01); A61K 45/06 (2006.01); A61K 9/08 (2006.01); A61K 31/00 (2006.01); A61K 9/00 (2006.01); A61K 31/401 (2006.01);
U.S. Cl.
CPC ...
A61K 31/351 (2013.01); A61K 9/0053 (2013.01); A61K 9/02 (2013.01); A61K 9/08 (2013.01); A61K 9/2009 (2013.01); A61K 9/2013 (2013.01); A61K 9/2018 (2013.01); A61K 9/2027 (2013.01); A61K 9/2059 (2013.01); A61K 9/4825 (2013.01); A61K 9/4858 (2013.01); A61K 9/4866 (2013.01); A61K 31/00 (2013.01); A61K 31/401 (2013.01); A61K 31/7034 (2013.01); A61K 38/28 (2013.01); A61K 45/06 (2013.01); C07D 309/10 (2013.01);
Abstract

The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a canine animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, insulin dependent diabetes mellitus, insulin resistance diabetes, insulin resistance, obesity, hyperglycemia, hyperglycemia induced cataract formation, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, inflammation of the pancreas, metabolic disorder consequences, such as hypertension, renal dysfunction and/or muscoskeletal disorders, and/or Syndrome X (metabolic syndrome), wherein preferably the development of hyperglycemia induced cataract formation is prevented or remission is achieved and/or wherein preferably the development of metabolic disorder consequences, such as hypertension, renal dysfunction and/or muscoskeletal disorders, is prevented or progression is slowed or remission is achieved.


Find Patent Forward Citations

Loading…